Driving innovation

in clinical research

Driving innovation

In Clinical Research

At the forefront of drug evolution

Leading the way in First-in-Human studies with a variety of patient populations.
Take your asset from First-in-Human to Proof of Concept in under one year with our specialist services.
Adaptive Phase I and II studies
Patient Recruitment
Thorough QT Studies
Bridging Studies
Data Management
III
Adaptive Phase III studies
View our specialist services
Adaptive Phase I and II studies
Patient Recruitment
Thorough QT Studies
Bridging Studies
Data Management
III
Adaptive Phase III studies
Take your asset from FIH to POC in under one year using our specialist services.

We are Richmond Pharmacology.

We are committed to advancing science and driving innovations in drug development.

We reduce drug development timelines using knowledge and expertise accumulated from over 500 clinical trials.

Centre of excellence.

Richmond Pharmacology is a centre for excellence for First-In-Human and early phase clinical studies. We reduce drug development timelines using our Adaptive Protocols and efficient Patient Recruitment.

Our sponsors are granted fast international marketing approvals due to our inclusive study design which fulfils the data requirements of global regulators.
As a full service CRO, our expertise spans consultancy and concept development through to final reporting. We work with leading experts in a multitude of therapy areas.
View our recent studies

Work with us

We work with leading genetic engineering organisations, top 10 pharma companies and dynamic biotechs to assess the safety and efficacy of new therapeutics.
By working with us, you will gain a research partner who can expedite your study start up, enable fast decisions and reduce your drug development timelines.
Our business ethos is unique
Our business is sustainable, adaptive to change and is led by the same specialists who founded Richmond Pharmacology in 2001. Our founders are involved in each clinical research trial, so you are assured of a personal service throughout.
Get in touch today

Latest news

Director of Operations, Keith Berelowitz, has been appointed as the Research Ethics Committee Chair for the Health Research Authority.

January 19, 2023
Keith Berelowitz will be responsible for ensuring that all ethical possibilities are explored in relation to new research.
Read more

Unlocking the potential of data sharing

January 4, 2023
Dilshat Djumonov explores how GDPR is central to protecting private information while presenting unique challenges to the pharmaceutical clinical trials industry.
Read more

Events

13th International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions

Sunday, June 4th to Tuesday June 6th 2023
Exchange research-based knowledge on drug-drug interactions (DDIs) among all interested stakeholders from pharmaceutical industry, regulatory authorities, academic and health care delivery backgrounds and perspectives.
View event